

Henry Ford Health

Henry Ford Health Scholarly Commons

Internal Medicine Meeting Abstracts

Internal Medicine

9-1-2021

1825P Prevalence of cancer among e-cigarette smokers compared to non-smokers: A retrospective cross-sectional survey study of NHANES-CDC

A Chidharla

R Rabbani

K Agarwal

S Abdelwahed

R Bhandari

See next page for additional authors

Follow this and additional works at: https://scholarlycommons.henryford.com/internalmedicine_mtgabstracts

Recommended Citation

Chidharla A, Rabbani R, Agarwal K, Abdelwahed S, Bhandari R, Manaktala PS, Singh A, Patel K, Singh P, Mehta D, Malik P, Patel U, Pillai S, and Koritala T. 1825P Prevalence of cancer among e-cigarette smokers compared to non-smokers: A retrospective cross-sectional survey study of NHANES-CDC. *Ann Oncol* 2021; 32:S1236.

This Conference Proceeding is brought to you for free and open access by the Internal Medicine at Henry Ford Health Scholarly Commons. It has been accepted for inclusion in Internal Medicine Meeting Abstracts by an authorized administrator of Henry Ford Health Scholarly Commons.

Authors

A Chidharla, R Rabbani, K Agarwal, S Abdelwahed, R Bhandari, P S. Manaktala, A Singh, K Patel, P Singh, D Mehta, P Malik, U Patel, Shreejith Pillai, and T Koritala

GENERAL INTEREST

1824P Attitudes, knowledge, and need for education about LGBTQ patients with cancer: A survey by the ESMO/SIOPE AYA with cancer Working Group

E. Saloustros¹, A. Ferrari², I. Bozovic-Spasojevic³, N. Gaspar⁴, G. Mountzios⁵, A. Blondeel⁶, S. Bielack⁷, D. Stark⁸, S. Jezdic⁹, F.A. Peccatori¹⁰

¹Department of Oncology, University Hospital of Larissa, Larissa, Greece; ²Pediatric Oncology Unit, Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy; ³Medical Oncology Department, Institute for Oncology and Radiology of Serbia, Belgrade, Serbia; ⁴Department of Oncology for Child and Adolescent, Gustave Roussy Cancer Campus, Villejuif, France; ⁵4th Department of Medical Oncology and Clinical Trials Unit, Henry Dunant Hospital, Athens, Greece; ⁶Department of Scientific Programme Coordination, European Society for Paediatric Oncology (SIOPE), Brussels, Belgium; ⁷Zentrum für Kinder, Jugend und Frauenmedizin Pädiatrie 5, Klinikum Stuttgart - Olghospital, Stuttgart, Germany; ⁸Leeds Institute of Medical Research, School of Medicine University of Leeds, Leeds, UK; ⁹Scientific and Medical Division, European Society for Medical Oncology (ESMO), Lugano, Switzerland; ¹⁰Division of Gynecologic Oncology, European Institute of Oncology IRCCS, Milan, Italy

Background: Sexual and gender minorities [lesbian, gay, bisexual, transgender, and queer/questioning (LGBTQ)] is a diverse group that is at risk for receiving disparate cancer care. A survey of the European Society for Medical Oncology (ESMO) and the European Society for Paediatric Oncology (SIOPE) members was conducted, to identify challenges in attitude and knowledge, as well as interest for further education about LGBTQ patients with cancer.

Methods: A link to an online survey was sent to the members of ESMO and SIOPE Europe to measure attitudes and knowledge about LGBTQ health, and clinical practices. Results were analyzed by using descriptive analyses.

Results: Among the 672 respondents, there was high agreement regarding the importance of knowing the gender identity as perceived by the patient (75%) and sex at birth (78%), which was contrasted by lower agreement (54%) regarding the importance of knowing sexual orientation. However, the majority doesn't ask about sexual orientation and gender identity during first visit (64% and 58% respectively). Only a minority of the respondents considered themselves well informed regarding gays/lesbians and transgender patients' health (44 and 25% respectively), and psychosocial needs (34%). Questions about cancer risk in relation to sexual orientation and in those who identify themselves as a different gender compared to risk estimated based on their gender at birth yielded mixed responses. There was high interest in receiving education regarding the unique health needs of LGBTQ patients (73%), which was considered as a core skill for all cancer specialists by 72%. For most of the questions no significant differences were noted among those who defined themselves as heterosexual, gays/lesbians or bisexual.

Conclusions: This is the largest, to our knowledge, and the first among European specialists survey, addressing attitude, knowledge and interest for further education needs about LGBTQ patients with cancer. A lack in knowledge about clinical and psychosocial issues was revealed, as well as high interest in receiving LGBTQ-specific education and clinical practice guidelines.

Legal entity responsible for the study: European Society for Medical Oncology (ESMO), European Society for Paediatric Oncology (SIOPE).

Funding: European Society for Medical Oncology (ESMO), European Society for Paediatric Oncology (SIOPE).

Disclosure: E. Saloustros: Financial Interests, Personal, Advisory Role: Roche Hellas; Financial Interests, Personal, Advisory Role: BMS; Financial Interests, Personal, Advisory Role: Pfizer Hellas; Financial Interests, Personal, Advisory Role: AstraZeneca; Financial Interests, Personal, Advisory Role: Amgen Hellas; Financial Interests, Personal, Advisory Role: Dimiourgiki Farmakeutikon Ypiresion AE; Financial Interests, Personal, Funding, Research: Astellas Pharma; Financial Interests, Personal, Other, Travel and Education support: Roche Hellas; Financial Interests, Personal, Other, Travel and Education support: Pfizer Hellas; Financial Interests, Personal, Other, Travel and Education support: Astellas Pharma; Financial Interests, Personal, Other, Travel and Education support: Novartis (Hellas); Financial Interests, Personal, Other, Travel and Education support: MSD Greece; Financial Interests, Personal, Other, Travel and Education support: Enorasis. I. Bozovic-Spasojevic: Financial Interests, Personal, Invited Speaker: Roche; Financial Interests, Personal, Invited Speaker: Novartis; Financial Interests, Personal, Invited Speaker: Pfizer; Financial Interests, Personal, Funding, PI: Roche; Financial Interests, Institutional, Funding, Clinical Trials : Roche. G. Mountzios: Financial Interests, Personal, Invited Speaker: AstraZeneca; Financial Interests, Personal, Invited Speaker: Roche; Financial Interests, Personal, Invited Speaker: MSD; Financial Interests, Personal, Invited Speaker: BMS; Financial Interests, Personal, Invited Speaker: Pfizer; Financial Interests, Personal, Invited Speaker: Takeda; Financial Interests, Personal, Invited Speaker: Janssen; Financial Interests, Personal, Invited Speaker: Novartis; Financial Interests, Personal, Invited Speaker: Sanofi; Financial Interests, Personal, Other, Consultancy fee : AstraZeneca; Financial Interests, Personal, Other, Consultancy fee : Roche; Financial Interests, Personal, Other, Consultancy fee : MSD; Financial Interests, Personal, Other, Consultancy fee : BMS; Financial Interests, Personal, Other, Consultancy fee : Novartis; Financial Interests, Personal, Other, Consultancy fee : Sanofi; Financial Interests, Personal, Funding, PI: AstraZeneca; Financial Interests, Personal, Funding, PI: Novartis; Financial Interests, Personal, Invited Speaker, PI: MSD; Financial Interests, Institutional, Funding, Clinical trials: AstraZeneca; Financial Interests, Institutional, Funding, Clinical trials : Novartis; Financial Interests, Institutional, Funding, Clinical trials : MSD. S. Bielack: Financial Interests, Personal, Advisory Board: Pfizer; Financial Interests,

Personal, Advisory Board: Bayer; Financial Interests, Personal, Advisory Board: Lilly; Financial Interests, Personal, Advisory Board: Novartis; Financial Interests, Personal, Advisory Board: Isfol. D. Stark: Financial Interests, Institutional, Research Grant: Teenage Cancer Trust. F.A. Peccatori: Financial Interests, Personal, Officer, Scientific Director : European School of Oncology; Financial Interests, Personal, Invited Speaker: Prime Oncology; Financial Interests, Personal, Invited Speaker: Takeda; Financial Interests, Personal, Advisory Board: Roche; Financial Interests, Personal, Advisory Board: AstraZeneca; Financial Interests, Personal, Advisory Board: Clovis; Financial Interests, Personal, Advisory Board: Ipsen. All other authors have declared no conflicts of interest.

<https://doi.org/10.1016/j.annonc.2021.08.712>

1825P Prevalence of cancer among e-cigarette smokers compared to non-smokers: A retrospective cross-sectional survey study of NHANES-CDC

A. Chidharla¹, R. Rabbani², K. Agarwal³, S. Abdelwahed⁴, R. Bhandari⁵, P.S. Manaktala⁶, A. Singh⁷, K. Patel⁸, P. Singh⁹, D. Mehta¹⁰, P. Malik¹¹, U. Patel¹¹, S. Pillai¹², T. Koritala¹³

¹Internal Medicine, University of Illinois College of Medicine at Peoria, Peoria, IL, USA; ²Internal Medicine, Temple University Hospital, Philadelphia, PA, USA; ³Internal Medicine, Hackensack Meridian Health Palisades Medical Center, North Bergen, NJ, USA; ⁴Department of Family and Community Medicine, University of Missouri, Kansas City, MO, USA; ⁵Department of Internal Medicine, Manipal College of Medical Sciences, Pokhara, Nepal; ⁶Department of Internal Medicine, Canton Medical Education Foundation/NEOMED, Canton, OH, USA; ⁷Department of Internal Medicine, Mount Sinai Morningside, New York, NY, USA; ⁸Department of Internal Medicine, Smt Kashibai Navale Medical College, Nahre, India; ⁹Internal Medicine, Apex Heart and Vascular Center, Passaic, NJ, USA; ¹⁰Internal Medicine, Clinical Research, Icahn School of Medicine at Mount Sinai, New York, NY, USA; ¹¹Public Health, Icahn School of Medicine at Mount Sinai, New York, NY, USA; ¹²Internal Medicine, Henry Ford Health System, Michigan, MI, USA; ¹³Internal Medicine, Mayo Clinic Health System, Mankato, MN, USA

Background: Current e-cigarette use has been rising, assuming as a safe alternative to traditional smoking. Therefore, we aim to evaluate the prevalence of cancer and types of cancers amongst e-cigarette and traditional smokers.

Methods: A retrospective cross-sectional survey study was performed using NHANES (National Health And Nutrition Examination Survey) database from 2015 to 2018. History of cancer (MCQ220), type of cancers (MCQ230a), and smoking status (E-cigarette: SMQ900 or SMQ905 and Traditional smoking: SMQ020) were identified. Univariate and multivariable logistic regression analysis was performed to find out prevalence and association between e-cigarette smoking and cancer. We have excluded respondents with dual smoking.

Results: Out of 154,856 participants, 7756 (5.01%) were e-cigarette users, 48625 (31.4%) were traditional smokers, 98475 (63.59%) were non-smokers. Females (49 vs 38%), Mexican Americans (20 vs 13%), high annual household income (>\$100,000: 23 vs 15%) were having a higher prevalence of e-cigarette smoking in comparison with traditional smoking. (p<0.0001) Prevalence of cancer (any type) was 11.61%. Cancer prevalence was higher amongst traditional smokers in comparison with e-cigarette smokers. (16.77 vs 2.32%; p<0.0001) E-cigarette smokers were younger at the diagnosis of 1st cancer in comparison with traditional smokers. (median: 45 vs 63-years; p<0.0001) Cervical (21.99 vs 2.01%), thyroid (10.64 vs 2.45%), leukemias (8.51 vs 1.08%), and breast (12.06 vs 12.01%) cancers were more prevalent amongst e-cigarette smokers in comparison to traditional smokers. (p<0.0001) In adjusted multivariable regression analysis, e-cigarette smokers [aOR: 1.3 (95%CI: 1.32-1.33); p<0.0001] and traditional smokers [1.6 (1.64-1.65); p<0.0001] were having higher odds of prevalence of cancer in comparison with non-smoker.

Conclusions: E-cigarette smokers had an early age of cancer onset and higher odds of cancer prevalence. Females had higher use of e-cigarette and cervical, thyroid, and breast cancers were prevalent amongst e-cigarette users. More prospective studies should be planned to mitigate the risk and before considering e-cigarette as a safe alternative to traditional smoking.

Legal entity responsible for the study: The authors.

Funding: Has not received any funding.

Disclosure: All authors have declared no conflicts of interest.

<https://doi.org/10.1016/j.annonc.2021.08.713>